Literature DB >> 20515779

Phytate levels and bone parameters: a retrospective pilot clinical trial.

Angel A Lopez-Gonzalez1, Felix Grases, Joan Perello, Fernando Tur, Antonia Costa-Bauza, Nieves Monroy, Bartolome Mari, Teofila Vicente-Herrero.   

Abstract

This study evaluated the relationship between phytate urinary levels and bone characteristics in a large population of postmenopausal women. The study population consisted of 180 postmenopausal women who participated in a descriptive cross-sectional study. A urine sample was collected from each subject to determine phytate levels and the volunteers were divided into two groups according to phytate urinary concentration (i.e., low and high levels). Bone mineral density was determined in the lumbar spine and femoral neck of groups with low and high phytate urinary levels. Urinary levels of phytate were linked to dietary phytate consumption. Hence, bone mineral density values were significantly higher in the lumbar spines and femoral necks of women who consumed high levels of phytate than in women with low urinary phytate concentrations. Higher urinary levels of phytate correlated with higher bone mineral density in the lumbar spine and femoral necks of postmenopausal women. This finding demonstrates the potential use of phytate in the treatment of bone related diseases, as it uses a mechanism of action similar to some bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20515779     DOI: 10.2741/e167

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  8 in total

1.  Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women.

Authors:  Angel A López-González; Félix Grases; Nieves Monroy; Bartolome Marí; Ma Teófila Vicente-Herrero; Fernando Tur; Joan Perelló
Journal:  Eur J Nutr       Date:  2012-05-22       Impact factor: 5.614

2.  A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.

Authors:  Carolina Salcedo; Pieter H Joubert; Miguel D Ferrer; Ana Z Canals; Francisco Maduell; Vicens Torregrosa; Josep Maria Campistol; Raquel Ojeda; Joan Perelló
Journal:  Br J Clin Pharmacol       Date:  2019-02-19       Impact factor: 4.335

3.  First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.

Authors:  J Perelló; P H Joubert; M D Ferrer; A Z Canals; S Sinha; C Salcedo
Journal:  Br J Clin Pharmacol       Date:  2018-10-03       Impact factor: 4.335

4.  SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels.

Authors:  Joan Perelló; M Gómez; M D Ferrer; N Y Rodríguez; C Salcedo; J M Buades; M M Pérez; J V Torregrosa; E Martín; F Maduell
Journal:  J Nephrol       Date:  2018-01-19       Impact factor: 3.902

5.  Urinary phytate concentration and risk of fracture determined by the FRAX indexzzm321990in a group of postmenopausal women

Authors:  Angel Arturo Lopez Gonzalez; Felix Grases; Bartolome Mari; Matias Tomas-Salva; Adrian Rodriguez
Journal:  Turk J Med Sci       Date:  2019-04-18       Impact factor: 0.973

6.  Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts.

Authors:  María del Mar Arriero; Joana M Ramis; Joan Perelló; Marta Monjo
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

7.  A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma.

Authors:  M D Ferrer; M M Pérez; M M Cànaves; J M Buades; C Salcedo; J Perelló
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

8.  Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification.

Authors:  Miguel D Ferrer; Markus Ketteler; Fernando Tur; Eva Tur; Bernat Isern; Carolina Salcedo; Pieter H Joubert; Geert J Behets; Ellen Neven; Patrick C D'Haese; Joan Perelló
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.